A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Ramucirumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2018 Planned End Date changed from 31 May 2021 to 31 Jul 2021.
- 13 Dec 2018 Planned primary completion date changed from 31 May 2021 to 31 Jul 2021.
- 13 Dec 2018 Planned initiation date changed from 30 Nov 2018 to 31 Jan 2019.